Marijuana Strategic Ventures, Inc. (OTC: MSVI) Announces Updates for Mushrooms, Inc., Health Product Production, Provisional Patent and Business Plan Development
Mushrooms, Inc. (OTC: MSVI) reported advancements in its three primary areas: Health, Innovation, and Research & Development. The company secured sourcing for six new Telogenix products, aiming for availability by September. They are building a team for the inaugural MYCO Experience event in California, set for 2023. Significant progress is being made in R&D with a provisional patent to repurpose green industrial waste into environmentally friendly products. A recent bipartisan bill on psychedelics research was also passed, enhancing prospects for the sector.
- Secured sourcing for six Telogenix products, enhancing product lineup.
- Inaugural MYCO Experience event planned for 2023, increasing brand visibility.
- Significant progress in R&D with a provisional patent aimed at green industrial waste applications.
- Bipartisan support for psychedelics research potentially beneficial for market growth.
- None.
ESTERO, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- Marijuana Strategic Ventures, Inc. (the “Company”) (OTC: MSVI) announces updates to the progress of its three areas of focus: Health, Innovation and Research & Development.
In Health, the Company has secured sourcing for the 4 Telogenix products currently listed on the website, www.mushroomsinc.com, as well as 2 additional products: one specific to athletes and another for removal of plaque from the arteries. All the ingredients are certified organic, non-GMO, gluten free and fair trade. The capsules for each product will be made and packaged in California. We are working towards the goal of product availability at the end of September. We are simultaneously working on product placement in organic focused, health-oriented stores as well as online.
For Innovation, we have begun to build the MYCO Experience team. We are currently looking at California for the location of the first MYCO Experience event and have 2023 as the projected year for the inaugural launch event. Social media for Mushrooms Inc. is guided by the MYCO Experience creative team. They are working on a monthly video format to educate about the world of mushrooms, connect that knowledge to innovation and grow an awareness and enthusiasm for this rapidly growing market. The 2023 MYCO Experience event looks to be the touch, taste and feel of the industry, as an Expo would be if it was integrated with beautiful live art and nature.
In Research and Development, we have made significant progress in filing our first provisional patent. We believe our new process will have end benefits in the medical industry while using green industrial waste as part of its composition. Outside the medical industry, we have aimed our end products to prolong the carbon hold of green waste through the creation of products with longevity of use. Rather than farmers burning the waste in fields, thus releasing the carbon it sequestered back into the atmosphere, we will repurpose the waste into green products and hold the carbon capture with credit valuation applied. When the product life cycle reaches its end, we are looking for results of quick, non-toxic decomposition in comparison to the current products in the market that we work to replace.
Kimberly Carlson, CEO of Mushrooms, Inc., commented, “I am working with a small and passionate team to create a 5-year business plan focused on bringing value to shareholders. I am excited about the current momentum as the major parts are coming together into a steady foundation of interconnected resources and creative passion.”
MSVI is also excited that the U.S. House of Representatives on Wednesday (July 13th) approved a bipartisan pair of psychedelics research amendments, as well as another measure requiring a military study into marijuana-related enforcement discrimination in the armed services. See the following article here for more details.
About Mushrooms Inc. (MSVI)
Mushrooms, Inc. is a publicly traded company on the OTC Markets with the stock symbol MSVI. We anticipate that the new ticker symbol for its Common Stock will be MYCO. We chose the trading symbol MYCO which is a prefix that denotes a relationship to fungus. From the Greek “mykes”, meaning fungus.
The vision for Mushrooms, Inc. is to support the growth of the mushroom industry through collaboration, innovation and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms, Inc. Our current focus is on the industrial application of Mycelium for the creation of carbon neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and Development is the path to achieving great innovation and the pioneers are the ones we look to for their fortitude and enduring dedication to the world of mycology. The working relationships we are fostering will result in scientifically proven products that advance health of body, mind and environment.
For more information, email info@mushroomsinc.com or visit www.mushroomsinc.com
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Corporate Contact:
Mushrooms, Inc.
CEO: Kimberly Carlson
Tel: (877) 379-5400
email: info@mushroomsinc.com
FAQ
What recent developments has Mushrooms, Inc. (MSVI) announced regarding their product line?
What is the MYCO Experience event planned by Mushrooms, Inc. (MSVI)?
What are the key focuses of Mushrooms, Inc. (MSVI) as reported in their latest press release?
How does the recent bipartisan bill affect Mushrooms, Inc. (MSVI)?
What progress has Mushrooms, Inc. (MSVI) made in research and development?
